No Data
No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
Phase III clinical study of recombinant human thrombopoietin injection (TPO) in the treatment of chronic liver disease-related thrombocytopenia achieved the preset primary endpoint.
Shenyang, July 26, 2024 / PRNewswire/ -- 3sbio (01530.HK) announced today that the phase III clinical study (Project Number: TPO106) of Recombinant Human Thrombopoietin Injection (Trade name: TPIAO) for the treatment of chronic liver disease-associated thrombocytopenia in patients undergoing elective invasive surgery has been completed and the results have achieved the pre-specified primary endpoint. 3sbio plans to submit a new indication application to the National Medical Products Administration in the near future. The primary efficacy endpoint of this phase III clinical trial is to verify the Recombinant Human Thrombopoietin Injection (
No Data